Identification of molecularly targeted therapy-induced immunopeptidome in diffuse midline glioma (DMG)

20260 citationsJournal Articlegold Open Access

Authors

Niloofar Khairkhah · University of Michigan

Habeebah Olufe Owolabi · Griffith University

Ali Namvar · University of Michigan

Mostafa M.H. Ibrahim · University of Michigan

Seeta Nyayapathy · Cayman Chemical (United States)

Richard H. Jones · BioWorks (United States)

Julie M. Rumble ·

Abstract

MTX-241F changes the glioma immunopeptidome, unveiling H2B1K, brain-enriched, and treatment-induced immunopeptides as immunologically visible targets. These findings provide a rationale for integrating molecularly targeted therapy with immunotherapeutic approaches to enhance tumor recognition and treatment efficacy in DMG and GBM.

Topics & Keywords

Glioma Diagnosis and Treatment vaccines and immunoinformatics approaches Ferroptosis and cancer prognosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neoplasia

Volume 73, pp. 101278-101278

DOI: 10.1016/j.neo.2026.101278

Field-Weighted Citation Impact: 0.00